Oncolytic adenoviruses have shown some promise in cancer gene therapy. However, their efficacy in clinical trials is often limited, and additional therapeutic interventions have been proposed to increase their efficacies. In this context, molecular imaging of viral spread in tumours could provide unique information to rationalize the timing of these combinations. Here, we use the human sodium iodide symporter (hNIS) as a reporter gene in wild-type and replication-selective adenoviruses. By design, hNIS cDNA is positioned in the E3 region in a wild-type adenovirus type 5 (AdIP1) and in an adenovirus in which a promoter from the human telomerase gene (RNA component) drives E1 expression (AdAM6). Viruses show functional hNIS expression and replication in vitro and kinetics of spread of the different viruses in tumour xenografts are visualized in vivo using a small animal nano-SPECT/CT camera. The time required to reach maximal spread is 48 h for AdIP1 and 72 h for AdAM6 suggesting that genetic engineering of adenoviruses can affect their kinetics of spread in tumours. Considering that this methodology is potentially clinically applicable, we conclude that hNIS-mediated imaging of viral spread in tumours may be an important tool for combined anticancer therapies involving replicating adenoviruses.
Introduction
Replication-competent 'oncolytic adenoviruses' have been used extensively in cancer therapies. 1 Their appeal resides in the fact that they are designed to replicate selectively in cancer cells. This self-amplification results in the spread of the virus in the tumour, leading to an improved therapeutic efficacy. 2 However, this efficacy needs further improvement since the spread in the tumour is often limited. 3, 4 Additional therapeutic interventions are required to obtain greater tumour reductions. 5, 6 For example, radiotherapy has been used in conjunction with the well-characterized oncolytic adenovirus ONYX-015 with beneficial responses. 7 More recently, administration of the prodrug ZD2767P in combination with an oncolytic adenovirus encoding the prodrug-activating enzyme carboxypeptidase G2 was shown to be highly effective in a murine model of colorectal carcinoma. 8 However, mistimed combination of additional therapy has already been described in preclinical studies, 9 resulting in loss of efficacy. In this context, the development of molecular imaging strategies capable of monitoring the propagation of oncolytic viruses in tumours is crucial to obtain an optimal therapeutic effect.
Oncolytic adenoviruses encoding different reporter systems for non-invasive bioluminescence or fluorescence imaging have been reported previously. [10] [11] [12] [13] [14] However, these imaging modalities have very limited applications in humans and to our knowledge, no reporter system using nuclear medicine technologies have been described for oncolytic adenoviruses.
The human sodium iodide symporter (hNIS) gene is endogenously expressed in the thyroid and stomach, and to a lower extent in the salivary glands, breast and thymus. 15 In the thyroid, it is physiologically responsible for iodide concentration. hNIS uses the sodium gradient generated from the Na + /K À ATPase to co-transport two Na + and one I À ions across the basolateral membrane of thyroid follicular cells 15 and is also key to the successful treatment of differentiated thyroid carcinomas with 131 I. 16 hNIS has been shown to allow accumulation of radioactive iodide endogenously and transduced exogenously expressing tissues for non-invasive imaging [17] [18] [19] [20] and is unlikely to interfere with the cell biochemistry. 21 Different modalities have been reported to image hNISexpressing tissues, including positron emission tomography (PET), [22] [23] [24] scintigraphic imaging 25 and single photon emission computed tomography (SPECT). 26 The imaging of hNIS-expressing tissues is particularly versatile since hNIS can promote cellular uptake of different radioisotopes 123 I (SPECT), 124 I (PET), 99m Tc (SPECT), 131 I (scintigraphic imaging). 19, [25] [26] [27] [28] In the present study, we have generated two replication-competent adenoviruses (AdIP1 and AdAM6) encoding the hNIS cDNA. AdIP1 is a 'wild-type' virus based on the Ad-5 serotype in which the only modification is the replacement of the gp19k gene in the E3 region by the hNIS cDNA. AdAM6 adenovirus also contains hNIS in place of gp19k, but encodes the cancer-specific human telomerase promoter (hTR, promoter of the RNA component of the telomerase complex) driving the expression of the E1 region. This promoter has previously been shown to be strong and tumour specific in non-replicating 23 and replicating adenoviruses. 29 These viruses were used to establish whether the hNIS imaging system could be used to visualize virus propagation in tumours in vivo, in the living animal.
Results

Adenoviral hNIS expression in vitro
To evaluate hNIS expression, HCT116 and SW620 cells were infected at a multiplicity of infection (MOI) 10 with either AdIP1 or AdAM6 and stained 24 h post-infection for hNIS expression. An hNIS-specific signal at the periphery of the infected cells was observed, suggesting that hNIS is correctly transported to the plasma membrane (Figures 1a and b) . Similar data were obtained with HCT116 cell lines (data not shown). Around 70% of the cells were hNIS-positive, suggesting that the position of hNIS cDNA in the E3 region of the adenoviral genome (replacing gp19k) is pertinent.
To test for hNIS functionality, HCT116 (Figure 1c ) or SW620 (Figure 1d) 24 (a replication-incompetent adenovirus in which hNIS expression is driven by the strong CMV promoter) showed a dose-dependent, perchlorate-sensitive 125 I uptake. The amplitude of this uptake was similar for all three viruses, demonstrating that hNIS expression driven by the endogenous adenovirus E3 promoter could provide high levels of transgene expression. Interestingly, positioning of the hNIS cDNA in the E1 locus led to a virus allowing far lower hNIS expression (not shown), emphasizing the importance of the positioning of the reporter gene in the adenoviral genome.
Adenoviral replication in vitro
To assess the replication potential of the various viruses and as E1a is a key mediator of viral replication, kinetics of E1a expression were determined by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). E1a mRNA was expressed from both AdIP1 and AdAM6 adenoviruses at all time points (Figure 2a ), I uptake analysis of HCT116 (c) and SW620 (d) cells in vitro in the presence and absence of hNIS inhibitor perchlorate (P). Cells were infected at MOI 1, 10 and 100 with adenoviruses AdIP1, AdAM6 and a non-replicating hNIS-expressing adenovirus Ad-CMV-hNIS. hNIS, human sodium iodide symporter; MOI, multiplicity of infection.
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A Merron et al while infection with the E1a-negative Ad-CMV-hNIS resulted in E1a levels of expression below the threshold of detection. For both AdIP1 and AdAM6, E1a levels increased until day 2 post-infection. These levels continued to increase on day 4 in AdAM6-infected cells, while they declined in AdIP1-infected cells. In terms of viral progeny, AdAM6 and AdIP1 were capable of producing equivalent amounts of virus up to day 4. However, by day 6, the titre of AdIP1 was higher than that of AdAM6 ( Figure 2b ).
Adenoviral hNIS expression in vivo
Subcutaneous HCT116 cells were grown as xenografts in nude mice and AdIP1 injected intratumorally at a dose of 5 Â 10 8 plaque forming units (PFU) on two consecutive days. Mice were then imaged at days 1 and 5. Figure 3a shows representative images of hNIS expression 1 day after the last virus infection. Concentration of 99-m Tc is observed in the thyroid and stomach as a result of endogenous NIS expression 22 and in the tumour. As expected from previous studies, no signal in the liver was observed upon intratumoral injection. 22, 23 Five days after virus administration (Figure 3b ), the tumours did not accumulate 99-m Tc, suggesting an absence of hNIS expression. To confirm these data, immunohistological stainings with an anti-hNIS antibody were performed on tumour sections obtained from animals scanned at day 1 or 5. Figure 3c shows an intense, brown, hNIS-specific signal in tumours at day 1 that had disappeared at day 5 ( Figure 3d ), largely confirming the SPECT scan data (Figures 3a and b) . In addition, RT-PCR for hNIS expression on tumours showed hNIS signal at day 1 that dramatically decreased by day 5 (data not shown), further confirming the imaging data. Imaging of animals injected with AdAM6 following a similar schedule also showed high levels of hNIS in the tumour at day 1 but no signal at day 5 (data not shown).
Kinetics of adenoviral spread in the tumour in vivo
Single dose of AdIP1 or AdAM6 (1 Â 10 9 PFU) were injected into HCT116 xenograft tumours. Animals were imaged at various time points post-infection. To obtain a greater resolution and as transgene expression was exclusively localized in the tumour (Figure 3 ), the scans were focussed on the tumour region. Throughout the 4 days, radiotracer uptake reflecting hNIS expression 24 can be seen spreading through the tumour for both viruses. Figure 4b) . Surprisingly, no further strong signal was detected in scans performed at days 6, 8 or 10 after viral administration (not shown).
Next, tumours infected with AdAM6 were collected at different time points and total DNA was extracted. An E1a-specific quantitative PCR assay was used to determine the viral DNA content. Figure 5 shows a dramatic increase in viral-specific DNA content of the tumour between days 1 and 2 after infection, corresponding to the replication of the virus. This viral DNA content remained constant at day 3 and gradually decreased at days 4 and 5. These data are compatible with the imaging data presented in Figure 4b and suggest a delay between the peak of viral replication and the peak of hNIS expression. After the peak, the viral DNA content in the tumour decreased rapidly, suggesting a viral clearance of the virus.
Finally, HCT116 xenografts were infected with different doses of AdAM6 and the animal cohort was imaged 3 days later. Figure 6 demonstrates that the peak of 99-m Tc uptake in the tumour is dose-dependent.
Discussion
We have generated and tested two oncolytic adenoviruses that exploit hNIS as a reporter gene. The maximal DNA size that can be packaged into a recombinant adenovirus has been estimated to 105% of the size of the 
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A Merron et al wild-type genome. 30 Therefore, an endogenous adenoviral gene had to be deleted to accommodate the hNIS cDNA (2 kb). We initially inserted hNIS in the E1b locus but the resulting virus was very weak compared to wildtype and showed low levels of hNIS expression (not shown). In the viruses presented in this report, hNIS cDNA replaces the gp19K gene in the E3 region of the adenovirus genome. This region was chosen for its previously-described ability to support transgene expression 31 and for the dispensable nature of gp19K. 13, 32 Using this design, both AdIP1 which is otherwise identical to the wild-type adenovirus and AdAM6 in which replication is driven by the hTR promoter 23, 29 show replication and functional hNIS expression in vitro. In vivo, the viruses demonstrate functional hNIS expression and importantly, the kinetics of adenoviral replication can be monitored using molecular imaging (Figures 3 and 4) . After intratumoral injection at day 0, the signal is weak at day 1 and reaches its peak at day 2 or 3 for AdIP1 and AdAM6, respectively. For AdAM6, we also demonstrate that this peak of signal in molecular imaging follows the peak of viral replication determined by measuring the viral DNA content in the tumour ( Figure 5 ). These data are consistent with a sequence of events in which first infection occurs, followed by replication of the virus and possibly packaging of the viral progeny that will infect neighbouring cells, leading to hNIS expression and radiotracer uptake upon imaging. Interestingly, this spread stops rapidly and no significant signal can be detected at day 5. At this stage, the remaining live cells in the tumour may be inaccessible to the virus or not permissive to adenoviral infection.
By comparison, non-invasive fluorescence imaging of the enhanced green fluorescent protein positioned in E3 of a wild-type adenovirus type 5 demonstrated a longlasting expression of the reporter gene. The peak of expression was reached 4 days after infection and expression remained constant until day 12.
13 Bioluminescence imaging has also been exploited to monitor reporter gene expression in a replicating adenovirus. 10 In these experiments, intratumoral injection of mice bearing intracranial tumours with an adenovirus encoding the luciferase gene resulted also in a rapidly decreasing reporter gene expression, supporting the transient nature of transgene expression in replication-selective adenoviruses observed in our study. The variability observed in these different studies may be attributed to different viral designs and/or to the half-life of the reporter protein used.
In our study, visualization of adenoviral propagation through the tumour mass demonstrates that genetic engineering in adenoviruses can result in differences in the kinetics of reporter gene expression in vivo. For AdIP1, the peak of radiotracer uptake is observed 48 h after infection while 72 h are required to reach this peak with AdAM6 (Figure 4) . In vitro, E1a expression upon infection of colorectal cancer cells with either virus was comparable up to day 2. At day 4, AdAM6 infection resulted in E1a RNA levels much greater than AdIP1 (Figure 2a ). This discrepancy may be due to differences in promoter driving E1a expression in the two viruses: the endogenous adenoviral promoter driving E1a in AdIP1 is subject to fine regulations 33, 34 and leads to E1a transient expression, while the hTR promoter in AdAM6 is constitutively active. As a result, AdAM6 infection produced lower amount of viral progeny than AdIP1 infection in vitro (Figure 2b ). In vivo, this difference in E1a expression may be contributing to the different kinetics of propagation of the viruses but the exact mechanism remains unclear.
To our knowledge, no reporter system using nuclear medicine technologies has been described for oncolytic adenoviruses and the availability of such system could provide a rationale for the combination of conventional therapies with oncolytic viruses or the optimal utilization of 'armed' oncolytic adenoviruses. For example, premature administration of ganciclovir post-infection with an oncolytic adenovirus encoding HSV-tk has been shown to result in decreased antitumour activity, possibly via loss of cells containing immature viral progeny. 9 The molecular imaging technology proposed in this manuscript could provide unique information to prevent mistimed administrations of the prodrug and the resulting virostatic effects. 9 Another application is the combination of the imaging and therapeutic potential of the hNIS transgene. 35 Oncolytic recombinant measles viruses encoding hNIS have already been described 36, 37 and used to demonstrate the concept of image-guided radiovirotherapy in a pre-clinical model of multiple myeloma. 36 Our work suggests the possibility to extend this concept to adenoviruses.
Considering that this methodology is potentially clinically applicable, we conclude that hNIS-mediated imaging of viral spread in tumours may be an important tool to rationalize combined anticancer therapies involving replicating adenoviruses in humans.
Materials and methods
Plasmids and viruses
The genomes of the adenoviruses AdIP1 and AdAM6 (cloned in the plasmids pIP1 and pAM15, respectively) were engineered by homologous recombination in yeast using a previously published methodology. [38] [39] [40] The virus AdIP1 is a wild-type adenovirus 5, in which the gp19k is replaced by the hNIS cDNA. The general design has already been described elsewhere. 31 The hNIS cDNA was amplified by PCR from pTGW10, 24 using the following primers: Forward: 5 0 -CTCTAGAGATGGAG GCCGTGGAGACCGGGGAACGG-3 0 ; Reverse: 5 0 -CCT CGAGGTCAGAGGTTTGTCTCCTGCTGGTCTCG-3 0 . Regions flanking the gp19K gene in the E3 locus were amplified using the primers: Forward: 5 0 -GCCGCGGC GATCAATTTATTCCTAACTTTGACGC-3 0 and Reverse: 5 0 -CTCTAGAGCTGCGCCTTTGGCCTAATAC-3 0 ; and Forward: 5 0 -CCTCGAGGCAATTGACTCTATGTGGGATAT GCTCC-3 0 and Reverse: 5 0 -GGGTACCCGAACATGTGT TTCAGTCCGTCCAATC-3 0 . All PCR products were cloned into pcDNA3.1/V5-His-TOPO (Invitrogen, Paisley, UK). The shuttle vector was assembled by cloning the three PCR fragments in pGV1 41 to create pIP7. IP7 was then used to modify the adenoviral genome by two-step gene replacement as described by Gagnebin et al. 38 and the plasmid pIP8 containing the entire wild-type adenovirus 5, in which the gp19k is replaced by the hNIS cDNA was created.
For the generation of pAM15, the expression cassette containing the hTR driving E1A cDNA (pAM2) was SPECT/CT imaging of oncolytic adenoviruses A Merron et al generated and excised using XhoI and NheI from plasmid pAM2 and cloned into pShuttle 42 to create pAM11. The plasmid pCF6
38 contains a 0.59 kb fragment corresponding to the E4 region/right ITR of Ad5. The desired shuttle vector (pAM13) was created by a triple ligation involving PacI-digested pCF1 38 and purified PacI/SalI inserts from pAM11 and pCF6 containing respectively the left ITR and the hTR driving the expression of E1A (5 0 -end of the adenovirus genome) and a 0.59 kb fragment corresponding to the 3 0 -end of the adenovirus genome. pAM13 was then linearized using SalI and cotransformed into YH587 yeast with a PacI-purified adenoviral backbone containing hNIS in place of gp19K (pIP8). Yeast transformation was performed using the alkali-cation yeast transformation kit (Qbiogene, San Diego, CA, USA) following the manufacturer's guidelines. Plasmids were purified from yeast by spheroplasting, 41 lysing and precipitating DNA that was then transformed into ElectroMAX DH10B bacteria (Invitrogen) following the manufacturer's guidelines.
Cell lines
The adenovirus producer cell line HEK293, and human colon adenocarcinoma SW620 and HCT116 cell lines were obtained from Cancer Research UK Cell Services (London, UK). All cell lines were maintained in the laboratory in Dulbecco's modified Eagle's medium containing 10% fetal calf serum at 37 1C.
Virus production
PacI-digested adenoviral plasmids (pIP8 and pAM13) were transfected into HEK293 cells and amplified through several rounds of infection in HEK293 cells. Viruses were purified by CsCl gradient ultracentrifugation as described previously 43 and dialysed against a solution containing 1 mM MgCl 2 ,10 mM Tris, pH7.4, 150 mM NaCl 2 and 10% glycerol. The viruses were then titrated to determine the number of infectious particles or PFU, as described previously. 24, 44 Immunofluorescence, iodide uptake assay and immunohistochemistry A total of 1 Â 10 6 cells were seeded onto sterile glass coverslips in a six-well plate. The next day, the cells were infected with various viruses and 24 h later they were washed and fixed with 4% paraformaldehyde for 15 min. Cells were then washed and permeabilized with 0.1% Triton X-100 for 5 min at 4 1C. Cells were washed again and primary hNIS antibody (clone FP5A; NeoMarkers, Fremont, CA, USA) added at 1:150 dilution in 500 ml for 30 min with gentle shaking. Cells were washed again and a 1:1000 dilution of anti-mouse 488 nm Alexafluor conjugate (Invitrogen, USA) in heat-inactivated fetal calf serum was added to the cells for 30 min in the dark. Cells were washed and nuclei counter-stained with 4,6-diamidino-2-phenylindole (Invitrogen, USA) at a 1:500 dilution for 5 min, cells rewashed and the coverslips were mounted onto slides. Iodide uptake was performed as described previously. 22 hNIS immunohistochemistry was performed as described previously. 45 
Reverse transcriptase-PCR
To determine viral E1A and hNIS mRNA transcription levels, we used a quantitative RT-PCR assay. Total mRNA was isolated from cells using the RNAeasy mini kit (Qiagen, Hilden, Germany) following the manufacturer's guidelines. The concentration of RNA extracted was measured using spectrophotometry at 260 nm. 
Viral replication assay
Cells were infected as described with Ad-wildtype, AdAM6 and Ad-CMV-hNIS (a non-replicating hNIScontaining virus 24 ) at MOI 5. At time points 24 h and 4 days post-infection, the cells and media were collected and freeze thawed three times by transferring from liquid nitrogen to 37 1C water bath. The lysate was then titrated on HEK293 cells in a 96-well plate from 10
À2
-to 10 À10 -fold viral dilutions and titre determined 10 days later.
Animals
All experiments were conducted with appropriate ethical approval and accordance with the Guidance on the Operation of the Animals (Scientific Procedures) Act 1986 (House of Commons 1990). Six-to eight-week-old BALB/c nu/nu mice were obtained from Harlan (Oxfordshire, UK), allowed to acclimatize for 1 week and were kept in individualized ventilated cages for the duration of the experiments and given food and water ad libitum.
HCT116 cells were grown as xenografts by injection of 2 Â 10 6 cells subcutaneously in the right flanks of BALB/ c nu/nu mice. When tumours reached approximately 200 mm 3 , they were given intratumoral injections of adenoviral preparations diluted in phosphate-buffered saline.
Nano-SPECT/CT imaging
Animals were anaesthetized with an intraperitoneal injection of ketamine/xyzaline (1.5 ml kg À1 at a 2:1 ratio) and then given an intravenous injection of 18.5 MBq of 99-m Tc. They were then positioned inside the SPECT/ CT scanner (Bioscan, Washington DC, WA, USA). The SPECT image was obtained and acquisition time depended on specific radioactivity levels in each mouse over the limits of the scan to obtain 100 000 c.p.s. A CT scan was taken at the same limits as the SPECT scan and all images were reconstructed with MEDISO software SPECT/CT imaging of oncolytic adenoviruses A Merron et al (Medical Imaging Systems). Fusion of SPECT and CT images was carried out using PMOD software.
